Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi.

Rousselle JC, Callister SM, Schell RF, Lovrich SD, Jobe DA, Marks JA, Wieneke CA.

J Infect Dis. 1998 Sep;178(3):733-41.

PMID:
9728542
2.

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.

Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, Hilton E, Kunkel M, Adler-Klein D, Doherty T, Evans J, Molloy PJ, Seidner AL, Sabetta JR, Simon HJ, Klempner MS, Mays J, Marks D, Malawista SE.

N Engl J Med. 1998 Jul 23;339(4):216-22. Erratum in: N Engl J Med 1998 Aug 20;339(8):571.

3.

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.

Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, Schoen RT, Nowakowski J, Schmid CH, Laukamp S, Buscarino C, Krause DS.

N Engl J Med. 1998 Jul 23;339(4):209-15.

4.

Lyme disease -- United States, 1996.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 1997 Jun 13;46(23):531-5.

7.

Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a "gold standard"?

Callister SM, Jobe DA, Schell RF, Pavia CS, Lovrich SD.

Clin Diagn Lab Immunol. 1996 Jul;3(4):399-402.

8.

Serodiagnosis of Lyme disease: accuracy of a two-step approach using a flagella-based ELISA and immunoblotting.

Johnson BJ, Robbins KE, Bailey RE, Cao BL, Sviat SL, Craven RB, Mayer LW, Dennis DT.

J Infect Dis. 1996 Aug;174(2):346-53.

PMID:
8699065
9.

In vitro inhibition of Borrelia burgdorferi growth by antibodies.

Sadziene A, Thompson PA, Barbour AG.

J Infect Dis. 1993 Jan;167(1):165-72.

PMID:
8418163
10.

Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test.

Callister SM, Schell RF, Case KL, Lovrich SD, Day SP.

J Infect Dis. 1993 Jan;167(1):158-64.

PMID:
8418162
12.

In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.

Levin JM, Nelson JA, Segreti J, Harrison B, Benson CA, Strle F.

Antimicrob Agents Chemother. 1993 Jul;37(7):1444-6.

13.

Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads.

Zabinski RA, Larsson AJ, Walker KJ, Gilliland SS, Rotschafer JC.

Antimicrob Agents Chemother. 1993 Jun;37(6):1377-9.

14.

Sera from patients with chronic Lyme disease protect mice from Lyme borreliosis.

Fikrig E, Bockenstedt LK, Barthold SW, Chen M, Tao H, Ali-Salaam P, Telford SR, Flavell RA.

J Infect Dis. 1994 Mar;169(3):568-74.

PMID:
8158028
15.

Detection of borreliacidal antibodies by flow cytometry. An accurate, highly specific serodiagnostic test for Lyme disease.

Callister SM, Schell RF, Lim LC, Jobe DA, Case KL, Bryant GL, Molling PE.

Arch Intern Med. 1994 Jul 25;154(14):1625-32.

PMID:
8031211
16.

Induction of an outer surface protein on Borrelia burgdorferi during tick feeding.

Schwan TG, Piesman J, Golde WT, Dolan MC, Rosa PA.

Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2909-13.

17.
18.

Differentiation of borreliacidal activity caused by immune serum or antimicrobial agents by flow cytometry.

Liu YF, Lim LC, Schell K, Lovrich SD, Callister SM, Schell RF.

Clin Diagn Lab Immunol. 1994 Mar;1(2):145-9.

19.

The antimicrobial removal device. A microbiological and clinical evaluation.

Wright AJ, Thompson RL, McLimans CA, Wilson WR, Washington JA 2nd.

Am J Clin Pathol. 1982 Aug;78(2):173-7.

PMID:
7048940
20.

Rapid isolation of bacteria from septicemic patients by use of an antimicrobial agent removal device.

Wallis C, Melnick JL, Wende RD, Riely PE.

J Clin Microbiol. 1980 May;11(5):462-4.

Supplemental Content

Support Center